
|Videos|August 18, 2022
Unmet Needs and the Future of AML Treatment
Author(s)Hetty E. Carraway, MD, Eytan Stein, MD
Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5




























